Supplemental Methods and Results for "Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlledmultiple-dose study"
Published: 12-02-2019| Version 1 | DOI: 10.17632/szb4ggs9rk.1
Contributor:
Description
Supplemental Methods and Results